These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32035635)

  • 21. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience.
    Gonski K; Chuang S; Teng A; Thambipillay G; Farrar MA; Menezes MP; Fitzgerald DA
    Neuromuscul Disord; 2023 Jun; 33(6):531-538. PubMed ID: 37290230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 23. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
    Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
    Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nusinersen in adults with type 3 spinal muscular atrophy: long-term outcomes on motor and respiratory function.
    Serrão C; Domingues S; de Campos CF; Moreira S; Conceição I; de Carvalho M; Oliveira Santos M
    Neurol Sci; 2024 Jun; 45(6):2887-2891. PubMed ID: 38589769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
    Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
    Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen.
    Gómez-García de la Banda M; Amaddeo A; Khirani S; Pruvost S; Barnerias C; Dabaj I; Bénézit A; Durigneux J; Carlier RY; Desguerre I; Quijano-Roy S; Fauroux B
    Pediatr Pulmonol; 2021 Jan; 56(1):299-306. PubMed ID: 33118682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory assessment in a spinal muscular atrophy infant treated with nusinersen.
    Ogawa K; Okanari K; Kobayashi O; Nakashima M; Ihara K
    Pediatr Int; 2019 Oct; 61(10):1051-1053. PubMed ID: 31612561
    [No Abstract]   [Full Text] [Related]  

  • 31. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
    Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
    N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sleep and Breathing After Nusinersen Therapy in a Child With Spinal Muscular Atrophy.
    Kouri I; Demirel N; Haile DT; Selcen D; Kotagal S
    J Clin Neuromuscul Dis; 2020 Dec; 22(2):105-108. PubMed ID: 33214397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy.
    Buonsenso D; Berti B; Palermo C; Leone D; Ferrantini G; De Sanctis R; Onesimo R; Curatola A; Fanelli L; Forcina N; Norcia G; Carnicella S; Lucibello S; Mercuri E; Pane M
    Pediatr Pulmonol; 2020 Jul; 55(7):1781-1788. PubMed ID: 32394611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An observational study of functional abilities in infants, children, and adults with type 1 SMA.
    Pane M; Palermo C; Messina S; Sansone VA; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Brigati G; de Sanctis R; Coratti G; Lucibello S; Bertini E; Vita G; Danilo Tiziano F; Mercuri E;
    Neurology; 2018 Aug; 91(8):e696-e703. PubMed ID: 30045959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function.
    Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; Brolatti N; Mizzoni I; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Salmin F; De Sanctis R; Pera MC; Piastra M; Genovese O; Ricci F; Cavallina I; Masson R; Zanin R; Agosto C; Salomon E; Bruno I; Magnolato A; Bertini E; Tiziano FD; Bovis F; Mercuri E;
    Eur J Neurol; 2023 Jun; 30(6):1755-1763. PubMed ID: 36880698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
    Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
    Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spinal muscular atrophy type 1: avoidance of hospitalization by respiratory muscle support.
    Ottonello G; Mastella C; Franceschi A; Bosticco D; Wolfler A; Pedemonte M; Esposito I; Gregoretti C
    Am J Phys Med Rehabil; 2011 Nov; 90(11):895-900. PubMed ID: 21955953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Spinal muscular atrophy treated with nusinersen].
    Boesen MS; Albrechtsen S; Born AP
    Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen.
    Coratti G; Pane M; Lucibello S; Pera MC; Pasternak A; Montes J; Sansone VA; Duong T; Dunaway Young S; Messina S; D'Amico A; Civitello M; Glanzman AM; Bruno C; Salmin F; Tacchetti P; Carnicella S; Sframeli M; Antonaci L; Frongia AL; De Vivo DC; Darras BT; Day J; Bertini E; Muntoni F; Finkel R; Mercuri E;
    Neuromuscul Disord; 2021 Jul; 31(7):596-602. PubMed ID: 34099377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.